Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Opinion: Discussing Genentech’s Ocrevus (ocrelizumab) to treat patients with multiple sclerosis with a neurologist

Ticker(s): RHHBY

Who's the expert?

Institution: Princeton and Rutgers Neurology

Board certified in Neurology and Board-certified Epilepsy specialist.
Currently manages 50 patients with multiple sclerosis.
Clinical interest in Neurology, epilepsy and seizures and also treats other neurological disorders including multiple sclerosis, headaches, migraines, stroke, Parkinson’s Disease, vertigo, and neck and back pain.

Interview Goal

The conversation will focus on the data from the Phase III OCARINA II trial evaluating Genentech’s Ocrevus® (ocrelizumab) as a twice a year 10-minute subcutaneous injection to treat patients with relapsing forms of MS or primary progressive MS (RMS or PPMS).

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.